Mersana Therapeutics Presents Pre-clinical Data at AACR-NCI-EORTC on Two Additional, Proprietary Antibody Drug Conjugate Plat...
November 12 2018 - 9:00AM
Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage
biopharmaceutical company focused on discovering and developing a
pipeline of antibody drug conjugates (ADCs) based on its
Dolaflexin® and other proprietary platforms, today announced it
will present data on two new, novel antibody-drug conjugate (ADC)
platforms at the AACR-NCI-EORTC International Conference on
Molecular Targets and Cancer Therapeutics taking place November
13-16, 2018, in Dublin, Ireland. Additionally, the company will
present pre-clinical data on the efficacy of XMT-1522 in NSCLC
patient-derived xenograft models."We are excited about the
potential of these novel, complementary ADC platforms to expand the
scope of our future drug development programs,” said Timothy B.
Lowinger, Ph.D., Chief Scientific Officer, Mersana Therapeutics.
“The Dolasynthen platform offers us a fully homogeneous platform to
control the drug-to-antibody ratio (DAR) precisely from 2-24 to
match it optimally to a given target. In addition, Alkymer, our
novel DNA damaging agent platform, provides us the ability to
address a broader range of cancer indications.”Details of the
presentations are as follows:
Title: Indole-Biaryl
Pyrrolobenzodiazepines (I-BiPs): A potent and well-tolerated class
of DNA mono-alkylating payload for antibody-drug conjugates
(ADCs)Date/Time: Tuesday, November 13 from 12:00 to 19:00
GMTPresenter: Josh Thomas, Ph.D., Principal Scientist The
poster demonstrates the potent antitumor efficacy for a novel
platform, Alkymer, in a variety of solid tumor models and favorable
therapeutic index and improved physicochemical properties relative
to competitor DNA alkylating ADC platforms. This platform will
allow Mersana to expand its development capabilities further into
different tumor types and broaden the patient population that may
benefit from these ADCs. Title: Discovery of the novel,
homogeneous payload platform Dolasynthen for Antibody-Drug
ConjugatesDate/Time: Thursday, November 15 from 10:00 – 17:30
GMTPresenter: Mariya Kozytska, Ph.D., Scientist This poster
demonstrates that the novel, fully homogeneous auristatin F
hydroxypropyl amide (AF-HPA) based payload platform, Dolasynthen,
showed potent in vivo antitumor activity and excellent tolerability
in non-human primate studies. The Dolasynthen platform is
amenable to the generation of ADCs with enhanced homogeneity,
including fully homogeneous ADCs. The poster details that the
hydrophilic nature of the structurally defined framework coupled
with the careful design of the payload and additional key
components led to identification of this novel platform, which
shows great promise for future clinical use. Title: Target
Expression/Efficacy Relationship of XMT-1522, a HER2-targeting
Antibody Drug Conjugate (ADC), in an Unselected Series of Non-small
Cell Lung Cancer (NSCLC) Primary Human Carcinoma
XenograftsDate/Time: Friday, November 16 from 10:00 to 14:00
GMTPresenter: Rebecca Mosher, M.D., Executive Director,
Translational Medicine Mersana’s final poster demonstrates
that in an unselected series of human primary xenografts, XMT-1522
yielded responses that related to HER2 protein and RNA expression
levels. A median best response of >50% reduction was seen in
8/16 NSCLC models in the 3 mg/kg treated group and 3/11 NSCLC
models in the 1 mg/kg treated group. HER2 protein levels will be
prospectively evaluated in the planned dose expansion groups as
part of the Phase 1 clinical trial of XMT-1522, and RNA levels will
be determined retrospectively. “We continue to make
significant strides in assembling the proprietary platforms
necessary to build a leadership ADC pipeline,” said Anna
Protopapas, President and CEO, Mersana Therapeutics. "We are
applying Dolaflexin, Dolasynthen and Alkymer platforms to our
priority targets and antibodies with the objective of selecting the
next generation of ADCs to bring into clinical development.
We are well poised to make a difference in patient
lives.” |
About XMT-1522
XMT-1522 is a Dolaflexin ADC targeting HER2-expressing tumors.
XMT-1522 comprises a proprietary HER2 antibody which is conjugated
with Mersana’s Dolaflexin platform – a Fleximer polymer linked
with a proprietary auristatin payload. XMT-1522 provides a drug
load of approximately 12 molecules per antibody, specifically
designed to improve potency while simultaneously increasing
tolerability. XMT-1522 has the potential to extend HER2-targeted
therapy beyond the current “HER2-positive” populations into
patients with lower levels of HER2 expression. The Phase 1 protocol
will evaluate XMT-1522 in patients with advanced HER2-positive
breast and gastric cancer, as well as advanced breast cancer with
low HER2 expression and non-small cell lung cancer. More
information on the ongoing Phase 1 clinical study can be found
at clinicaltrials.gov.
About Mersana TherapeuticsMersana Therapeutics
is a clinical-stage biopharmaceutical company using its
differentiated and proprietary ADC platforms to develop highly
targeted drugs with increased tolerability and expanded
opportunities to deliver meaningful clinical benefit to
patients. Mersana’s product candidate XMT-1522 is in Phase 1
clinical trials in patients with advanced tumors expressing HER2,
including breast cancer, non-small-cell-lung-cancer (NSCLC) and
gastric cancer patients. The Company’s second product candidate,
XMT-1536, is in Phase 1 clinical trials in patients with tumors
expressing NaPi2b, including ovarian cancer, NSCLC and other
cancers. In addition, multiple partners are using Mersana’s
platform to advance their ADC pipelines.Media
Contact Paul Kidwell paulkidwell@mersana.com
617-680-1088Investor Contact Stern Investor
Relations, Inc. Christina Tartaglia christina@sternir.com
212-362-1200
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Mersana Therapeutics (NASDAQ:MRSN)
Historical Stock Chart
From Sep 2023 to Sep 2024